

## Comprehensive Characterization of the N and O-Linked Glycosylation of a Recombinant Human EPO

---

Matthew A. Lauber, Stephan M. Koza, Erin E. Chambers

Waters Corporation

---

### Abstract

This application note demonstrates the use of two facile strategies that can be used to detail both the N and O-linked glycosylation of recombinant, human epoetin (rhEPO), a molecule which has been perceived to be challenging to characterize due to its relatively complicated glycosylation. Collectively, these tools could be used to accelerate the development of new biosimilars.

### Benefits

- Two facile strategies to elucidate information about both the N and O-linked glycosylation of EPO
  - Unprecedented HILIC separations of high antennarity released N-glycans and intact protein glycoforms
  - MS compatible HILIC to enable detailed investigations of sample constituents
  - ACQUITY UPLC Glycoprotein BEH Amide Column (300Å, 1.7 µm stationary phase) is QC tested via a glycoprotein separation to ensure consistent batch-to-batch reproducibility
-

---

## Introduction

The immunoglobulin G (IgG) modality has paved the way for many efficacious protein-based therapies.<sup>1</sup> At the same time, numerous highly effective patient therapies have also been made possible by the production of recombinant, human hormones and enzymes. For example, erythropoiesis stimulating therapeutics, like epoetin (EPO) alpha, have long been available for the treatment of anemia. Such a therapy for increasing patient red blood cell counts was first made possible by the commercialization of Epogen,<sup>®</sup> which has been available in the US market since its approval by the FDA in 1989.<sup>2</sup> And now, because the landscape of the biopharmaceutical industry continues to evolve and Epogen patents expired in 2013,<sup>3</sup> EPO drug products are targets for being developed into both international and domestic-market biosimilars.

Epoetin alpha has a relatively small primary structure, yet it has 3 sites of N-glycosylation and 1 site of O-glycosylation (Figure 1).<sup>4</sup> Because of its glycosylation, epoetin alpha has a molecular weight between 30 and 40 kDa even though its protein mass amounts to only 18 kDa. Interestingly, the glycosylation of epoetin is very much tied to its potency and serum half life. Two attributes of its glycan profile that are known to show positive correlations with in vivo activity include antennarity and sialylation.<sup>5-7</sup> As a result, it is critical for the glycosylation of an epoetin therapeutic to be well characterized. In addition, the significance of epoetin glycosylation suggests that detailed glycan profiling would be a path toward establishing a viable epoetin biosimilar.




Figure 1. Sequence and structural information for recombinant, human epoetin alpha (rhEPO).

## Experimental

### Sample description

A recombinant, human epoetin alpha expressed from CHO cells (PeproTech, Rocky Hill, NJ) was reconstituted in 50 mM HEPES NaOH pH 7.9 buffer to a concentration of 2 mg/mL.

N-glycans were released from rhEPO and labeled with *Rapi*Fluor-MS using a GlycoWorks *Rapi*Fluor-MS N-Glycan Kit and the instructions provided in its care and use manual (p/n: 715004793). *Rapi*Fluor-MS labeled N-glycans were injected as a mixture of 90  $\mu$ L SPE eluate, 100  $\mu$ L dimethylformamide, and 210  $\mu$ L acetonitrile.

To facilitate analysis of O-glycosylation, rhEPO was N-deglycosylated using the rapid deglycosylation technique outlined in the care and use manual of the GlycoWorks *Rapi*Fluor-MS N-Glycan Kit (p/n: 715004793).

## Method conditions (unless otherwise noted)

### Column Conditioning

New (previously unused) ACQUITY UPLC Glycoprotein BEH Amide, 300Å, 1.7 µm Columns should be conditioned via two or more sequential injections and separations until a consistent profile is achieved. The care and use manual of the column can be referred to for more information (p/n: 720005408EN).

### LC conditions for RapiFluor-MS Released N-Glycans

LC System:	ACQUITY UPLC H-Class Bio System
Sample temp.:	10 °C
Analytical column temp.:	60 °C
Flow Rate:	0.4 mL/min
Injection Volume:	10 µL
Column:	ACQUITY UPLC Glycoprotein BEH Amide, 300Å, 1.7 µm, 2.1 x 150 mm (with Glycoprotein Performance Test Standard)
Fluorescence detection:	Ex 265 nm / Em 425 nm, 2 Hz
Sample collection/Vials:	Sample Collection Module  Polypropylene 12 x 32 mm Screw Neck vial, 300 µL volume
Mobile phase A:	50 mM ammonium formate, pH 4.4 (LC-MS grade; from a 100x concentrate
Mobile phase B:	ACN (LC-MS grade)

## Gradient

Time	Flow Rate (mL/min)	%A	%B	Curve
0.0	0.4	25.0	75.0	6.0
35.0	0.4	46.0	54.0	6.0
36.5	0.2	100.0	0.0	6.0
39.5	0.2	100.0	0.0	6.0
43.1	0.2	25.0	75.0	6.0
47.6	0.4	25.0	75.0	6.0
55.0	0.4	25.0	75.0	6.0

## MS conditions for RapiFluor-MS Released N-Glycans

MS system:	Xevo G2-XS QTof
Ionization mode:	ESI+
Analyzer mode:	Resolution (~40 K)
Capillary voltage:	2.2 kV
Cone voltage:	75 V
Source temp.:	120 °C

Desolvation temp.:	500 °C
Source offset:	50 V
Desolvation gas flow:	600 L/Hr
Calibration:	NaI, 1 µg/µL from 100–2000 <i>m/z</i>
Acquisition:	700–2000 <i>m/z</i> , 0.5 sec scan rate
Lockspray:	300 fmol/µL Human glufibrinopeptide B in 0.1% (v/v) formic acid, 70:30 water/acetonitrile every 90 seconds
Data management:	MassLynx Software v4.1

## LC conditions for Intact Protein HILIC of N-Deglycosylated rhEPO

LC system:	ACQUITY UPLC H-Class Bio System
Sample temp.:	10 °C
Analytical column temp.:	45 °C
Flow rate:	0.2 mL/min
Fluorescence detection:	Ex 280 nm/Em 320 nm (Intrinsic fluorescence), 10 Hz
Mobile phase A:	0.1% (v/v) TFA, H <sub>2</sub> O
Mobile phase B:	0.1% (v/v) TFA, ACN

HILIC injection volume:	1.3 $\mu$ L (A 2.1 mm I.D. HILIC column can accommodate up to an $\sim$ 1 $\mu$ L aqueous injection before chromatographic performance is negatively affected)
Columns:	ACQUITY UPLC Glycoprotein BEH Amide, 300Å, 1.7 $\mu$ m, 2.1 x 150 mm Column (with Glycoprotein Performance Test Standard)
Vials:	Polypropylene 12 x 32 mm Screw Neck, 300 $\mu$ L volume

## Gradient

Time	%A	%B	Curve
0.0	15.0	85.0	6.0
0.5	15.0	85.0	6.0
1.0	25.0	75.0	6.0
21.0	35.0	65.0	6.0
22.0	100.0	0.0	6.0
24.0	100.0	0.0	6.0
25.0	15.0	85.0	6.0
35.0	15.0	85.0	6.0

## MS conditions for Intact Protein HILIC of N-Deglycosylated rhEPO

MS system:	SYNAPT G2-S HDMS
Ionization mode:	ESI+
Analyzer mode:	Resolution (~20 K)
Capillary voltage:	3.0 kV
Cone voltage:	45 V
Source offset:	50 V
Source temp.:	150 °C
Desolvation temp.:	500 °C
Desolvation gas flow:	800 L/Hr
Calibration:	NaI, 1 µg/µL from 500–5000 m/z
Acquisition:	700–4800 <i>m/z</i> , 1 sec scan rate
Data management:	MassLynx Software v4.1

In this application note, we demonstrate the use of two facile strategies that can be used to detail the N and O-linked glycosylation of a recombinant, human epoetin (rhEPO). In this work, rhEPO N-glycans were rapidly released, labeled with GlycoWorks Rapi Fluor-MS and profiled by hydrophilic interaction chromatography (HILIC) using sensitive fluorescence and mass spectrometric detection. Then, in a second, parallel analysis, N-deglycosylated rhEPO was interrogated by intact protein HILIC to elucidate information on O-glycosylation.



---

## Results and Discussion

### Released N-Glycan analysis of rhEPO using RapiFluor-MS labeling and HILIC profiling

The glycosylation of recombinant, human epoetin (rhEPO) has been investigated many times before.<sup>4-5, 8-13</sup> In large part, these previous studies have required relatively involved techniques. With this work, it was our objective to establish two facile and complementary, LC based approaches for the analysis of EPO, one capable of providing information about N-glycosylation and the other information about O-glycosylation.

A profile of the N-glycans from rhEPO can be readily obtained with a new sample preparation strategy involving the novel glycan labeling reagent, *RapiFluor*-MS. This sample preparation, based on the GlycoWorks *RapiFluor*-MS N-Glycan Kit, allows an analyst to rapidly release N-glycans and label them with a tag that provides enhanced sensitivity for fluorescence and electrospray ionization mass spectrometric (ESI-MS) detection.<sup>14</sup> In previous applications, *RapiFluor*-MS has been predominately used in the analysis of different IgG samples.<sup>14-16</sup> Nevertheless, using the protocol from the GlycoWorks *RapiFluor*-MS N-Glycan Kit, an analyst can successfully prepare samples from even heavily glycosylated proteins, such as rhEPO.

*RapiFluor*-MS labeled N-glycans have proven to be amenable to hydrophilic interaction chromatography (HILIC). Accordingly, HILIC-fluorescence-MS of *RapiFluor*-MS has emerged as a very powerful tool for detailing the N-glycosylation of proteins.<sup>14</sup>

To this end, a sample of *RapiFluor*-MS N-glycans derived from rhEPO was profiled using HILIC. A recently introduced widepore amide column, the ACQUITY UPLC Glycoprotein BEH Amide, 300Å, 1.7 µm Column, was selected for this work to obtain high resolution N-glycan separations. This column was purposefully designed to facilitate HILIC separations of large molecules, such as glycopeptide and glycoproteins. However, the widepore particle architecture has also been shown to increase the peak capacity of highly branched, tri- and tetra-antennary N-glycans by 10–20%,<sup>17</sup> making it an ideal choice for the HILIC profiling of EPO N-glycans, which typically exhibit high antennarity. Figure 2A shows the HILIC fluorescence and base peak intensity (BPI) MS chromatograms of the *RapiFluor*-MS N-glycans resulting from 0.4 µg of rhEPO. Even with this relatively limited amount of sample, high signal-to-noise chromatograms are obtained. The sensitivity of the fluorescence trace allows for accurate, relative quantitation across the profile. The signal-to-noise of the MS chromatogram is also particularly noteworthy, though it should be noted that MS sensitivity decreases as N-glycan structures become

larger. Nevertheless, the quality of these particular data is made possible by use of the *RapiFluor*-MS reagent in combination with the Xevo G2-XS QToF, a new generation MS instrument with improved transmission efficiency and sensitivity. This QToF technology provides unprecedented sensitivity as well as high mass resolution, as can be observed in the collection of mass spectra in Figure 2B that have been used to support the assignment of various N-glycan species.




Figure 2. HILIC profiling of released N-glycans from rhEPO. (A) Fluorescence and (B) base peak intensity (BPI) chromatograms for *RapiFluor*-MS labeled N-glycans from rhEPO. Chromatograms obtained for glycans from 0.4  $\mu\text{g}$  protein using an ACQUITY UPLC Glycoprotein BEH Amide, 300Å, 1.7  $\mu\text{m}$ , 2.1 x 150 mm Column. (C) MS spectra for four example N-glycan species. N-glycan assignments are listed according to Oxford notation. "+Ac" denotes an acetylation, such as the previously reported O-acetylation of sialic acid residues (Neu5Ac).<sup>8</sup>

The chromatographic and MS-level selectivity afforded by this analysis simplifies making N-glycan assignments such that the species of the rhEPO N-glycan profile were easily mapped (Figure 3).

The rhEPO analyzed in this study exhibits an N-glycan profile comprised primarily of tetra-antennary, tetrasialylated N-glycans (FA4G4S4) with varying N-acetyl lactosamine extensions. However, the profile also shows a highly abundant peak that corresponds to a disialylated, biantennary N-glycan (FA2G2S2). Given that the ratio of tetra-antennary to biantennary N-glycans has a positive correlation with the in vivo activity of an EPO,<sup>6</sup> this analysis has clearly produced valuable information. Other information that can be readily obtained from this N-glycan analysis includes the degree of sialylation and the extent to which structures are modified with lactosylamine extensions. Overall, these results demonstrate that a very-information rich N-glycan profile can indeed be obtained from a comparatively simple RapiFluor-MS N-glycan preparation and a corresponding HILIC-fluorescence-MS analysis.

RT (min)	Species	MW <sub>Mono, Theo</sub> (Da)	Observed <i>m/z</i>	<i>z</i>	MW <sub>Mono, Obs</sub> (Da)	Mass error (ppm)
16.21	FA2G2S1	2388.9201	1195.4659	2	2388.9172	1.2
18.12	FA2G2S2	2680.0155	894.3492	3	2680.0258	-3.8
22.24	FA3G3S3	3336.2432	1113.0924	3	3336.2554	-3.7
23.68	FA4G4S4 + Ac	4034.4813	1345.8372	3	4034.4898	-2.1
24.15/24.60	FA4G4S3	3701.3754	1234.7966	3	3701.368	2.0
25.52	FA4G4S4	3992.4708	1331.8309	3	3992.4709	0.0
25.7	FA4G4Lac1S4 + Ac	4399.6135	1467.5425	3	4399.6057	1.8
26.16/26.66	FA4G4Lac1S3	4066.5076	1356.5104	3	4066.5094	-0.4
27.34	FA4G4Lac1S4	4357.6030	1090.4097	4	4357.6097	-1.5
27.95	FA4G4Lac2S3	4431.6397	1108.9143	4	4431.6281	2.6
28.97	FA4G4Lac2S4	4722.7352	1181.6909	4	4722.7345	0.1
29.66	FA4G4Lac3S3	4796.7719	1200.2004	4	4796.7725	-0.1
30.50	FA4G4Lac3S4	5087.8674	1272.976	4	5087.8749	-1.5
31.77	FA4G4Lac4S4	5452.9996	1364.256	4	5452.9949	0.9

Figure 3. LC-MS data supporting the identification of various released N-glycan species. “+Ac” denotes an acetylation, such as the previously reported O-acetylation of sialic acid residues (Neu5Ac).<sup>8</sup>

## Profiling the O-Glycosylation of Intact rhEPO using a Widepore Amide HILIC Separation

O-linked glycans can be challenging to characterize due to the paucity of high fidelity mechanisms to release them from their counterpart proteins. Released glycan analysis is an attractive approach for the characterization of N-glycans because of the simplicity and effectiveness of PNGase F deglycosylation. In place of using an analogous, universal glycosidase, analysts have resorted to releasing O-linked glycans by chemical means, such as alkaline beta elimination<sup>18</sup> or hydrazinolysis.<sup>19</sup> These release mechanisms can be challenging to implement and can very often produce artifacts, known as peeling products.

Rather than attempt a released O-glycan analysis of rhEPO, we looked to develop an alternative characterization strategy. A novel workflow was devised that first involved subjecting the rhEPO to rapid deglycosylation using GlycoWorks Rapid PNGase F and 1% *Rapi*Gest SF surfactant. In a 10-minute preparation, a sample of N-deglycosylated intact rhEPO was obtained that could then be profiled via a HILIC separation with an ACQUITY UPLC Glycoprotein BEH Amide Column. Figure 4 presents the chromatogram obtained in this analysis using intrinsic fluorescence detection and intact protein HILIC techniques that have been described in previous work.<sup>20</sup> The N-deglycosylated rhEPO analyzed in this study resolved into a series of approximately 10 peaks. Online ESI-MS provided highly detailed information, allowing for proteoforms of rhEPO to be assigned to the various chromatographic peaks. The two most abundant LC peaks were found to be represented by deconvoluted masses of 18893.8 and 19185.3 Da, which are consistent with N-deglycosylated rhEPO that has a C-terminal arginine truncation as well as trisaccharide and tetrasaccharide O-linked glycan modifications, respectively. More specifically, the mass shift observed for the lighter species is indicative of a glycan modification comprised of 1 hexose, 1 N-acetylhexosamine, and 1 N-acetylneuraminic acid. Meanwhile, the mass shift observed for the heavier species suggests a glycan modification comprised of the same structure with an additional N-acetylneuraminic acid.




Figure 4. HILIC-fluorescence-MS analysis of N-deglycosylated, intact rhEPO. (A) Fluorescence chromatogram demonstrating O-linked glycan heterogeneity and occupancy. Chromatograms obtained from 0.7  $\mu$ g protein using a 2.1 x 150 mm ACQUITY UPLC Glycoprotein BEH Amide, 300Å, 1.7  $\mu$ m, 2.1 x 150 mm Column. (B) Deconvoluted mass spectra corresponding to three of the major rhEPO proteoforms. Peak identifications, in addition to those denoted here, are tabulated in Figure 5.

Further investigation of the LC-MS data also showed that the proteoform of rhEPO that is aglycosylated with respect to the O-linked glycan eluted with a retention time of approximately 8.2 min. Moreover, these LC-MS data indicated there to be at least two additional O-linked glycoforms and even more C-terminal truncation proteoforms (Figure 5). Here, it is seen that this workflow can indeed be used to rapidly profile the O-linked glycosylation of an rhEPO, such that information is gained about both occupancy and heterogeneity.



RT (min)	Species	MW <sub>Avg, Theo</sub> (Da)	MW <sub>Avg, Obs</sub> (Da)	Mass Error (Da)
8.0	N-deglycosylated, –C-term GDR	18066.5	18065.2	-1.3
	N-deglycosylated, –C-term DR	18123.6	18122.4	-1.2
<b>8.2</b>	<b>N-deglycosylated, –C-term R</b>	<b>18238.7</b>	<b>18237.4</b>	<b>-1.3</b>
<b>9.3</b>	<b>N-deglycosylated, –C-term R +Hex1HexNAc1Neu5Ac1+Ac</b>	<b>18937.3</b>	<b>18936.2</b>	<b>-1.1</b>
9.5	N-deglycosylated, –C-term GDR +Hex1HexNAc1Neu5Ac1	18723.1	18722.3	-0.8
	N-deglycosylated, –C-term DR +Hex1HexNAc1Neu5Ac1	18780.1	18779.1	-1.0
<b>9.7</b>	<b>N-deglycosylated, –C-term R +Hex1HexNAc1Neu5Ac1</b>	<b>18895.2</b>	<b>18893.8</b>	<b>-1.4</b>
<b>9.9</b>	<b>N-deglycosylated, –C-term R +Hex1HexNAc1Neu5Ac2+Ac</b>	<b>19228.5</b>	<b>19227.3</b>	<b>-1.2</b>
<b>10.0</b>	<b>N-deglycosylated, –C-term R +Hex1HexNAc1Neu5Ac1 + O</b>	<b>18911.2</b>	<b>18910.0</b>	<b>-1.2</b>
10.2	N-deglycosylated, –C-term GDR +Hex1HexNAc1Neu5Ac2	19014.3	19013.7	-0.6
<b>10.5</b>	<b>N-deglycosylated, –C-term R +Hex1HexNAc1Neu5Ac2</b>	<b>19186.5</b>	<b>19185.3</b>	<b>-1.2</b>
<b>10.8</b>	<b>N-deglycosylated, –C-term R +Hex1HexNAc1Neu5Ac2 + O</b>	<b>19202.5</b>	<b>19201.2</b>	<b>-1.3</b>

Figure 5. LC-MS data supporting the identification of various N-deglycosylated rhEPO proteoforms. “–C-term” denotes the C-terminal truncation of the rhEPO; losses of different residues are noted. Hex, HexNAc, and Neu5Ac stand for hexose, n-acetylhexosamine, and N-acetylneuraminic acid. For example, Hex1HexNAc1Neu5Ac1 corresponds to O-glycosylation involving 1 hexose, 1 N-acetylhexosamine, and 1 N-acetylneuraminic acid. “+O” denotes a mass shift indicative of the addition of an oxygen atom, such as an oxidation or an exchange of Neu5Ac for Neu5Gc. Data supporting identifications of the most abundant rhEPO sequence variant (–C-term R) and its glycoforms are highlighted with bold text. “+Ac” denotes an acetylation, such as the previously reported O-acetylation of sialic acid residues (Neu5Ac).<sup>8</sup>

---

## Conclusion

Several powerful tools have recently emerged for the analysis of glycans that are built upon LC-MS compatible hydrophilic interaction chromatography (HILIC). At the heart of these new glycan analysis workflows is a HILIC column that has been purposefully designed for large molecule separations. With this ACQUITY UPLC Glycoprotein BEH Amide Column, an analyst can achieve higher resolution separations of large, released N-glycans. And when this analysis is paired with RapiFluor-MS labeling, a technique is established that affords not only high resolution but also unprecedented sensitivity. This approach has been successfully applied to obtain highly detailed information about the N-glycosylation of a recombinant, human epoetin alpha (rhEPO). Given that N-glycosylation correlates with the half life and activity of an EPO, such information, with its unparalleled quality, would be invaluable in developing a new EPO therapeutic. EPO is also O-glycosylated; the occupancy and heterogeneity of which could also be critical to demonstrate comparability among different drug substances. Using the ACQUITY UPLC Glycoprotein BEH Amide Column, we have outlined a simple sample preparation and subsequent HILIC separation that is capable of profiling these O-glycan attributes on intact rhEPO. In summary, we have demonstrated the use of two facile strategies that can be used to detail both the N and O-linked glycosylation of recombinant, human epoetin (rhEPO), a molecule which has been perceived to be challenging to characterize due to its relatively complicated glycosylation. Collectively, these tools could be used to accelerate the development of new biosimilars.

---

## References

1. An, Z., Monoclonal antibodies – a proven and rapidly expanding therapeutic modality for human diseases. *Protein Cell* 2010, 1 (4), 319–30.
2. Bennett, C. L.; Spiegel, D. M.; Macdougall, I. C.; Norris, L.; Qureshi, Z. P.; Sartor, O.; Lai, S. Y.; Tallman, M. S.; Raisch, D. W.; Smith, S. W.; Silver, S.; Murday, A. S.; Armitage, J. O.; Goldsmith, D., A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR). *Semin Thromb Hemost* 2012, 38 (8), 783–96.

3. US\$67 billion worth of biosimilar patents expiring before 2020 2012. <http://www.gabionline.net/Biosimilars/General/US-67-billion-worth-of-biosimilar-patents-expiring-before-2020>.
  4. Rush, R. S.; Derby, P. L.; Smith, D. M.; Merry, C.; Rogers, G.; Rohde, M. F.; Katta, V., Microheterogeneity of erythropoietin carbohydrate structure. *Anal Chem* 1995, 67 (8), 1442–52.
  5. Dube, S.; Fisher, J. W.; Powell, J. S., Glycosylation at specific sites of erythropoietin is essential for biosynthesis, secretion, and biological function. *J Biol Chem* 1988, 263 (33), 17516–21.
  6. Takeuchi, M.; Inoue, N.; Strickland, T. W.; Kubota, M.; Wada, M.; Shimizu, R.; Hoshi, S.; Kozutsumi, H.; Takasaki, S.; Kobata, A., Relationship between sugar chain structure and biological activity of recombinant human erythropoietin produced in Chinese hamster ovary cells. *Proc Natl Acad Sci USA* 1989, 86 (20), 7819–22.
  7. Takeuchi, M.; Takasaki, S.; Shimada, M.; Kobata, A., Role of sugar chains in the in vitro biological activity of human erythropoietin produced in recombinant Chinese hamster ovary cells. *J Biol Chem* 1990, 265 (21), 12127–30.
  8. Harazono, A.; Hashii, N.; Kuribayashi, R.; Nakazawa, S.; Kawasaki, N., Mass spectrometric glycoform profiling of the innovator and biosimilar erythropoietin and darbepoetin by LC/ESI-MS. *J Pharm Biomed Anal* 2013, 83, 65–74.
  9. Sasaki, H.; Bothner, B.; Dell, A.; Fukuda, M., Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. *J Biol Chem* 1987, 262 (25), 12059–76.
  10. Takeuchi, M.; Takasaki, S.; Miyazaki, H.; Kato, T.; Hoshi, S.; Kochibe, N.; Kobata, A., Comparative study of the asparagine-linked sugar chains of human erythropoietins purified from urine and the culture medium of recombinant Chinese hamster ovary cells. *J Biol Chem* 1988, 263 (8), 3657–63.
  11. Rush, R. S.; Derby, P. L.; Strickland, T. W.; Rohde, M. F., Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis. *Anal Chem* 1993, 65 (14), 1834–42.
  12. Gimenez, E.; Benavente, F.; Barbosa, J.; Sanz-Nebot, V., Analysis of intact erythropoietin and novel erythropoiesis-stimulating protein by capillary electrophoresis-electrospray-ion trap mass spectrometry. *Electrophoresis* 2008, 29 (10), 2161–70.
  13. Gimenez, E.; Benavente, F.; de Bolos, C.; Nicolas, E.; Barbosa, J.; Sanz-Nebot, V., Analysis of recombinant
-



- human erythropoietin and novel erythropoiesis stimulating protein digests by immunoaffinity capillary electrophoresis-mass spectrometry. *J Chromatogr A* 2009, 1216 (12), 2574–82.
14. Lauber, M. A.; Yu, Y. Q.; Brousmiche, D. W.; Hua, Z.; Koza, S. M.; Magnelli, P.; Guthrie, E.; Taron, C. H.; Fountain, K. J., Rapid Preparation of Released N-Glycans for HILIC Analysis Using a Labeling Reagent that Facilitates Sensitive Fluorescence and ESI-MS Detection. *Anal Chem* 2015, 87 (10), 5401–9.
  15. Lauber, M. A.; Brousmiche, D. W.; Hua, Z.; Koza, S. M.; Guthrie, E.; Magnelli, P.; Taron, C. H.; Fountain, K. J., Rapid Preparation of Released N-Glycans for HILIC Analysis Using a Novel Fluorescence and MS-Active Labeling Reagent. Waters Application Note 720005275EN 2015.
  16. Eoin F.J. Cosgrave, M. A. L., Robert Birdsall, and Sean M. McCarthy, New Capabilities for Monitoring Released N-Glycans through the Combined Use of RapiFluor-MS Labeling, ACQUITY UPLC H-Class Bio System, and Serial Fluorescence/ACQUITY QDa Mass Detection. Waters Application Note 720005352EN 2015.
  17. Lauber, M. A.; Koza, S. M., Enhancing the Peak Capacity of High Molecular Weight N-Glycan HILIC Separations with a Wide-Pore Amide Bonded Stationary Phase. Waters Technology Brief 720005381EN 2015.
  18. Huang, Y.; Mechref, Y.; Novotny, M. V., Microscale nonreductive release of O-linked glycans for subsequent analysis through MALDI mass spectrometry and capillary electrophoresis. *Anal Chem* 2001, 73 (24), 6063–9.
  19. Patel, T. P.; Parekh, R. B., Release of oligosaccharides from glycoproteins by hydrazinolysis. *Methods Enzymol* 1994, 230, 57–66.
  20. Lauber, M. A.; Koza, S. M., Developing High Resolution HILIC Separations of Intact Glycosylated Proteins Using a Wide-Pore Amide-Bonded Stationary Phase Waters Application Note 720005380EN 2015.

---

## Featured Products

ACQUITY UPLC H-Class Bio System <<https://www.waters.com/10166246>>

Xevo G2-XS ToF Time-of-Flight Mass Spectrometry <<https://www.waters.com/134798183>>

SYNAPT G2-Si High Definition Mass Spectrometry <<https://www.waters.com/134740622>>

MassLynx MS Software <<https://www.waters.com/513662>>

---

## Available for purchase online:

ACQUITY UPLC Glycoprotein BEH Amide, 300Å, 1.7 µm, 2.1 mm X 150 mm Column <

<https://www.waters.com/waters/partDetail.htm?partNumber=176003702>>

Glycoworks Sample Collection Module <

<https://www.waters.com/waters/partDetail.htm?partNumber=186007988>>

Polypropylene 12 x 32mm Screw Neck Vial <

<https://www.waters.com/waters/partDetail.htm?partNumber=186002640>>

Waters Ammonium Formate Solution – Glycan Analysis <

<https://www.waters.com/waters/partDetail.htm?partNumber=186007081>>

Glycoworks RapiFluor-MS N-Glycan Kit <

<https://www.waters.com/waters/partDetail.htm?partNumber=176003911>>

720005462, August 2015

©2019 Waters Corporation. All Rights Reserved.